Revance to Present Three New Abstracts Evaluating DaxibotulinumtoxinA for Injection and Two ePosters Evaluating the RHA® Collection During the American Society for Dermatologic Surgery (ASDS) Virtual Annual Meeting
- Two oral presentations highlighting new data on DaxibotulinumtoxinA for Injection from the SAKURA Phase 3 program, the largest aesthetic neuromodulator clinical program ever conducted for the treatment of glabellar (frown) lines –
- One oral presentation featuring new interim analysis data from a Phase 2a open-label study on the safety and efficacy of DaxibotulinumtoxinA for Injection for the treatment of lateral canthal lines (crow’s feet) –
- In addition, there will be two ePosters evaluating the properties of hyaluronic acid-based dermal fillers –
- Revance to also host ‘Innovative Technology for the Emerging Demand of Facial Dynamics’ virtual symposium at ASDS on
“These data underscore the potential of DaxibotulinumtoxinA for Injection to set a new standard in facial aesthetics treatments and advance our mission of transforming the patient experience,” said
The first presentation will report on the efficacy, duration, and safety of DaxibotulinumtoxinA for Injection in females across multiple age cohorts following the treatment of glabellar lines in the SAKURA program. This subgroup analysis demonstrated that the efficacy and duration of DaxibotulinumtoxinA for Injection for the treatment of glabellar lines is similarly high in adult females independent of age. The second presentation will highlight details from the SAKURA program in which DaxibotulinumtoxinA for Injection treated subjects showed substantial and progressive improvement in the severity of glabellar lines at rest following repeated treatment.
The final presentation will cover 4-week interim data from the Phase 2a open-label study in crow's feet. Data demonstrated that following treatment of LCLs with DaxibotulinumtoxinA for Injection, 88% of subjects achieved a score of none or mild at Week 4 in at least one treatment group. DaxibotulinumtoxinA for Injection appeared to be well tolerated at all dose levels. These results were previously announced by Revance in
DaxibotulinumtoxinA for Injection Demonstrates Consistent Efficacy, Duration, and Safety in Females Independent of Age: Subgroup Analysis from a Large, Phase 3 Program
Friday, October 9, 2020, 9:36 a.m.– 9:39 a.m. ETduring the Session #1: Oral Abstracts.
Glynis Ablon, M.D., FAAD, Dermatologist at Ablon Skin Institute and Research Center, Manhattan Beach, CA, and Associate Clinical Professor at University of California, Los Angeles, CA, USA
DaxibotulinumtoxinA for Injection–treated subjects show progressive improvement in static glabellar lines with repeated treatment
Friday, October 9, 2020, 9:42 a.m.– 9:45 a.m. ETduring the Session #1: Oral Abstracts.
Richard Glogau, M.D., Dermatologist at Glogau Dermatology, San Francisco, CA, and Clinical Professor of Dermatology University of California, San Francisco, CA, USA
DaxibotulinumtoxinA for Injection for Lateral Canthal Lines: A 4-week Interim Analysis
Friday, October 9, 2020, 9:39 a.m.– 9:42 a.m. ETduring the Session #1: Oral Abstracts.
Terrence Keaney, M.D., FAAD, Dermatologist at SkinDC Cosmetic Center, Arlington, VA, Assistant Clinical Faculty of Dermatology at George Washington Universityand Howard University, and Director of the Laser and Lipoatrophy Clinicat the Veterans Affairs Hospital, Washington, D.C.
Rheological Evaluation of the
Dynamic Propertiesof Hyaluronic Acid-based Dermal Fillers
Vince Bertucci*, Conor Gallagher†, Jimmy Faivre‡, Kevin Legent‡, Mélanie Gallet‡, Elodie Tremblais‡, François Bourdon‡
University of Toronto, Toronto, Ontario, Canadaand private practice, Woodbridge, Ontario, Canada; † Revance Therapeutics, Inc., Newark, California; ‡Teoxane, Geneva, Switzerland
Evaluation of the Impact of Hyaluronic Acid (HA) Filler Manufacturing Technologies on HA Chain Degradation
Jay Mashburn†, Jimmy Faivre‡, François Bourdon‡
Revance Therapeutics, Inc., Newark, California; ‡Teoxane, Geneva, Switzerland
Revance is anticipating the
Complete abstracts, details on presentation times and changes to presentation dates can be found on the ASDS website. The above listed dates are subject to change. Please check www.asds.net for the latest information.
“Revance Therapeutics” and the Revance logo are registered trademarks of
RHA resilient hyaluronic acid® and RHA® are trademarks of
BOTOX® is a registered trademark of
This press release contains forward-looking statements, including statements related to Revance’s financial outlook, milestone expectations, expected cash runway and financial performance; the planned commercial launch of our RHA® Collection of dermal fillers and the HintMD fintech platform, the process and timing of, and ability to complete, current and anticipated future clinical development of our investigational drug product candidates; the initiation, design, enrollment, submission, timing and results of our clinical studies, including the near-term milestone expectations described above; development of a biosimilar to BOTOX®; results of our non-clinical programs; statements about our business strategy, timeline and other goals and market for our anticipated products, plans and prospects, including our commercialization plans; statements about our ability to obtain, and the timing relating to, regulatory approval with respect to our drug product candidates, including with respect to the anticipated approval of DaxibotulinumtoxinA for Injection in glabellar lines and expected PDUFA date; and potential benefits of our drug product candidates and our technologies, including with respect to the RHA® line of dermal fillers and HintMD fintech platform.
Forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially from our expectations. These risks and uncertainties include, but are not limited to: the outcome, cost, and timing of our product development activities and clinical trials; the uncertain clinical development process, including the risk that clinical trials may not have an effective design or generate positive results; our ability to obtain and maintain regulatory approval of our drug product candidates, including our ability to receive timely approval of DaxibotulinumtoxinA for Injection; our ability to obtain funding for our operations; our plans to research, develop, and commercialize our drug product candidates; our ability to achieve market acceptance of our drug product candidates; unanticipated costs or delays in research, development, and commercialization efforts; the applicability of clinical study results to actual outcomes; the size and growth potential of the markets for our drug product candidates; our ability to successfully commercialize our drug product candidates and the timing of commercialization activities and anticipated product launches; the rate and degree of market acceptance of our drug product candidates; our ability to develop sales and marketing capabilities; the accuracy of our estimates regarding expenses, future revenues, capital requirements and needs for financing; our ability to continue obtaining and maintaining intellectual property protection for our drug product candidates; and the impact of the COVID-19 pandemic on our manufacturing operations, supply chain, business operations, commercialization efforts, end user demand for our products, clinical trials and other aspects of our business. Detailed information regarding factors that may cause actual results to differ materially from the results expressed or implied by statements in this press release may be found in Revance's periodic filings with the
“Revance Therapeutics” and the Revance logo are registered trademarks of
- Bertucci V, et al. “DaxibotulinumtoxinA for Injection has a prolonged duration of response in the treatment of glabellar lines: Pooled data from two multicenter, randomized, double-blind, placebo-controlled, phase 3 studies (SAKURA 1 and SAKURA 2).” J Am Acad Dermatol. 2019;82(4):838-845. doi: https://doi.org/10.1016/j.jaad.2019.06.1313
Fabi SG, et al. “DaxibotulinumtoxinA for Injection for the Treatment of Glabellar Lines: Efficacy Results From SAKURA 3, a Large, Open-Label, Phase 3 Safety Study.” Dermatologic Surgery. Published online
August 6, 2020. doi: 10.1097/DSS.0000000000002531
Green JB, et al. “A Large, Open-Label, Phase 3 Safety Study of DaxibotulinumtoxinA for Injection in Glabellar Lines: A Focus on Safety From the SAKURA 3 Study.” Dermatologic Surgery. Published online
August 6, 2020. doi: 10.1097/DSS.0000000000002463
- Clinicaltrials.gov. “Efficacy and Safety of Increasing Doses of DaxibotulinumtoxinA for Injection (DAXI for Injection) in the Treatment of Moderate or Severe Lateral Canthal Lines.” Available at: https://clinicaltrials.gov/ct2/show/NCT03911102?term=DaxibotulinumtoxinA.
Jenifer Slaw, 347-971-0906
Nadine Tosk, 504-453-8344